InflaRx (NASDAQ:IFRX) has been given an average recommendation of â€œBuyâ€ by the nine research firms that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $11.00.
IFRX has been the subject of several research analyst reports. Lifesci Capital restated a â€œmarket performâ€ rating on shares of InflaRx in a research note on Friday, October 30th. SVB Leerink raised shares of InflaRx from a â€œmarket performâ€ rating to an â€œoutperformâ€ rating and upped their target price for the company from $7.00 to $10.00 in a report on Friday, November 6th. Ci Capital reissued a â€œholdâ€ rating and issued a $7.00 price objective on shares of InflaRx in a research note on Monday, September 14th. Zacks Investment Research cut shares of InflaRx from a â€œbuyâ€ rating to a â€œholdâ€ rating in a research note on Wednesday. Finally, HC Wainwright assumed coverage on shares of InflaRx in a research note on Thursday, October 8th. They issued a â€œbuyâ€ rating and a $11.00 price objective for the company.
NASDAQ IFRX traded down $0.14 on Friday, reaching $5.62. The company had a trading volume of 15,101 shares, compared to its average volume of 588,665. The firm has a market cap of $147.64 million, a price-to-earnings ratio of -3.40 and a beta of 0.52. InflaRx has a fifty-two week low of $2.52 and a fifty-two week high of $9.70. The business has a 50 day moving average of $4.60 and a two-hundred day moving average of $4.58.
InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($0.29) earnings per share for the quarter, beating the Zacksâ€™ consensus estimate of ($0.36) by $0.07. On average, equities research analysts forecast that InflaRx will post -1.42 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC acquired a new position in InflaRx during the 1st quarter worth approximately $9,609,000. Bank of America Corp DE increased its position in InflaRx by 184.7% during the second quarter. Bank of America Corp DE now owns 21,900 shares of the companyâ€™s stock worth $101,000 after buying an additional 14,209 shares during the period. Verition Fund Management LLC acquired a new position in InflaRx during the second quarter worth approximately $436,000. Engineers Gate Manager LP acquired a new position in InflaRx during the second quarter worth approximately $67,000. Finally, Schonfeld Strategic Advisors LLC increased its position in InflaRx by 63.3% during the second quarter. Schonfeld Strategic Advisors LLC now owns 35,240 shares of the companyâ€™s stock worth $162,000 after buying an additional 13,655 shares during the period. Institutional investors and hedge funds own 13.73% of the companyâ€™s stock.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases.
Further Reading: Why is a lock-up period needed for an IPO?
Receive News & Ratings for InflaRx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for InflaRx and related companies with MarketBeat.com’s FREE daily email newsletter.